You are here:
26 July 2018 / deal

Acquisition of Takeda Chromo by Shanghai Pharmaceuticals Holding Co.

Loyens & Loeff advised Shanghai Pharmaceuticals on the acquisition of Takeda Chromo Beteiligungs AG.

The Belgian ‘Cayman tax’ and its impact on wealth and estate planning in Belgium

Shanghai Pharmaceuticals Holding Co. (Hong Kong) announced the entering into a share purchase agreement with Takeda AG, a wholly-owned subsidiary of Takeda Japan (listed on the Tokyo Stock Exchange) to acquire 100% of the issued and outstanding share capital of Takeda Chromo Beteiligungs AG. Upon completion of the USD 144 million acquisition, Shanghai Pharmaceuticals will increase its direct and indirect shareholding in Techpool Bio-pharma Co., Ltd, a global leader in natural urine protein drugs, to approximately 67,14%. The acquisition is, among other conditions, still subject to approval by the China National Market Supervision Administration.

Loyens & Loeff advised Shanghai Pharmaceuticals Holding Co. as Swiss transaction counsel on this acquisition. The team was led by partner Marco Toni (Corporate / M&A, Switzerland) and consisted of Jana Bieli (Corporate / M&A, Switzerland) and Rebecca Kühne (Tax, Switzerland).

 



letstalklegal-blue

Shareholder activism: Minority rights and shareholder lawsuits

Changes to minority rights and shareholder lawsuits potentially affecting shareholder activism in Switzerland in the future. read more
Written resolutions of the board of directors

Written resolutions of the board of directors

Valérie Schrämli has recently published a short article about written resolutions in the board of directors of Swiss companies read more
Due Diligence For Swiss CBD Companies

Due Diligence for Swiss CBD Companies

Switzerland has proven to provide for attractive conditions for businesses involved in the production and distribution of cannabidiol (CBD) products. read more